Jane Street
EPRX

Jane Street’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Jane Street’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.16M Buy
329,053
+293,843
+835% +$2.03M ﹤0.01% 5034
2026
Q1 		$254K Buy
35,210
+5,588
+19% +$45K ﹤0.01% 9594
2025
Q4 		$223K Buy
+29,622
New +$183K ﹤0.01% 9507

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Jane Street's EPRX Position: Q2 2026 in Review

Jane Street increased its Eupraxia Pharmaceuticals (EPRX) stake by 835% in Q2 2026, buying an estimated $2.03M and bringing the position to 329,053 shares worth $2.16M. The position accounts for ﹤0.01% of the portfolio, ranked #5034.

Jane Street first reported a position in EPRX in Q4 2025 and has held it in 3 quarters since. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Jane Street held 329,053 shares of Eupraxia Pharmaceuticals worth $2.16M as of Q2 2026.
  • Jane Street bought 293,843 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $2.03M.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #5034 holding.
  • Jane Street first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.